|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
At the township level, APRI≥ 0.7 and FIB-4≥ 3.5 were highly correlated with HCV infection (r = 0.95, p<0.001 in APRI and r = 0.809, p<0.001 in FIB-4) and hepatocellular carcinoma (HCC) development (r = 0.894, p<0.001 in APRI and r = 0.804, p<0.001 in FIB-4), but not correlated with HBV infection.
|
31639131 |
2019 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
When the patients were divided into three groups (0-0.1%: n = 27, 0.1%-10%: n = 34, 10-100%: n = 29), based on the deletion frequency, FIB-4 (p < 0.01), HBV DNA (p < 0.01), HBcrAg (p < 0.01) and preS1/S2 start codon mutations (p < 0.01, both) were significantly associated with the deletion.
|
30794632 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
407 consecutive patients with HBeAg-negative HBV infection who underwent pSWE, transient elastography (TE) as well as laboratory fibrosis markers, including fibrosis index based on four factors (FIB-4), aspartate to platelet ratio index (APRI) and FibroTest, on the same day were prospectively followed up for six years.
|
31810183 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 529 hepatitis B e antigen seroconverters with fibrosis-4 (FIB-4) index ≤ 3.6 not on nucleos(t)ide analogue therapy were included.
|
28914957 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prevalence of synCRLM was compared between hepatitis B surface antigen (HBsAg)-positive and -negative patients; significant predictors for synCRLM were analyzed by logistic regression analysis; Fibrosis-4 Index for Liver Fibrosis (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), and hepatitis B e antigen (HBeAg) status were compared between patients with or without synCRLM.
|
29293940 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, FIB-4 index of 1.29 was able to stratify all the risks of adverse liver events even in HBeAg-negative patients with a low risk of disease progression (HBV DNA <2000 IU/mL, HBsAg <1000 IU/mL and ALT <40 U/L).
|
29601647 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overall diagnostic value of FIB-4 is not very high for liver fibrosis in patients with hepatitis B.
|
28060754 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS ARFI, APRI, and FIB-4 can assess liver fibrosis in patients with hepatitis B when assessing the portal venous pressure.
|
28735336 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the diagnostic accuracy of aspartate aminotransferase (AST)-to-platelet ratio index (APRI), fibrosis-4 index (FIB-4), AST/alanine aminotransferase (ALT) ratio (AAR), and age-platelet index (API) for significant fibrosis (Metavir F2-4) in low-replicative (HBV DNA <20,000 IU/mL) chronic hepatitis B virus (HBV) patients.
|
28841822 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase.
|
28883700 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, serum GP73 is an accurate serum marker for significant fibrosis in chronic HBV infection, with higher accuracy than APRI and FIB-4.
|
29082644 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the performance of aspartate transaminase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4) to predict significant fibrosis and cirrhosis in hepatitis B virus e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients with alanine transaminase (ALT) ≤ twice the upper limit of normal (2 ULN).Histologic and laboratory data of 236 HBeAg-negative CHB patients with ALT ≤ 2 ULN were analyzed.
|
28328813 |
2017 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate whether long-term low-level hepatitis B virus (HBV) DNA influences dynamic changes of the FIB-4 index in chronic hepatitis B (CHB) patients receiving entecavir (ETV) therapy with partial virological responses.
|
26604649 |
2015 |